Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triptorelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 3/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.66 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.59 |
| ▸ | APLNR | P35414 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triptorelin SCHEMBL16815056 | 1.00 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL1371630 | 1.00 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL5079698 | 1.00 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL1652722 | 1.00 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| SCHEMBL11678163 | 0.99 | PTGS1 (0.73) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL29459903 | 0.99 | PTGS1 (0.72) | PTGS1GNRHRABCC2C5AR1APLNR | |
| SCHEMBL29373920 | 0.98 | PTGS1 (0.72) | PTGS1GNRHRABCC2C5AR1CXCR4 | |
| SCHEMBL29914777 | 0.98 | PTGS1 (0.72) | PTGS1GNRHRABCC2C5AR1APLNR | |
| SCHEMBL1319486 | 0.98 | PTGS1 (0.71) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Gonadorelin SCHEMBL143114 | 0.98 | PTGS1 (0.71) | PTGS1GNRHRABCC2C5AR1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250064896-A1 | METHODS, COMPOSITIONS AND USES FOR TREATING CANCER BY PROVIDING MEDICATIONS THAT INDUCE TARGETED TUMOR CELL MITOSIS BEFORE PROVIDING CHEMOTHERAPY OR RADIATION AND KITS THEREFOR | MAISON AMORI OQVPO LLC | 2025-02-27 | — | — | US | claimed |
| EP-4473131-A1 | A METHOD OF PREDICTING RISK OF AN AGGRESSIVE OR RECURRENT CANCER | OncoAssure Limited (IE) | 2024-12-11 | — | — | EP | claimed |
| WO-2024239281-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| US-20240344133-A1 | A METHOD OF PREDICTING RISK OF AN AGGRESSIVE OR RECURRENT CANCER | ONCOASSURE LIMITED (IE) | 2024-10-17 | — | — | US | claimed |
| WO-2024052896-A1 | COMBINATION OF THERAPEUTIC AGENTS AND METHOD FOR USE THEREOF FOR TREATMENT AND PREVENTION OF ENDOCRINE, AUTOIMMUNE AND NEUROLOGICAL DISORDERS | LEVICURE LTD. (IL) | 2024-03-14 | — | — | WO | claimed |
| WO-2023186985-A1 | A METHOD OF PREDICTING RISK OF AN AGGRESSIVE OR RECURRENT CANCER | ONCOASSURE LIMITED (IE) | 2023-10-05 | — | — | WO | claimed |
| EP-4253567-A1 | A METHOD OF PREDICTING RISK OF AN AGGRESSIVE OR RECURRENT CANCER | OncoAssure Limited (IE) | 2023-10-04 | — | — | EP | claimed |
| WO-2023150267-A1 | METHODS, COMPOSITIONS AND USES FOR TREATING CANCER BY PROVIDING MEDICATIONS THAT INDUCE TARGETED TUMOR CELL MITOSIS BEFORE PROVIDING CHEMOTHERAPY OR RADIATION AND KITS THEREFOR | MAISON AMORI OQVPO LLC (US) | 2023-08-10 | — | — | WO | claimed |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | claimed |
| EP-3041509-B1 | NKR3 ANTAGONISTS FOR TREATING OR PREVENTING HOT FLUSHES | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2023-07-12 | — | — | EP | claimed |
| US-20230165931-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-06-01 | — | — | US | claimed |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2023-04-13 | — | — | US | claimed |
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-02-23 | — | — | US | claimed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | claimed |
| US-20220096518-A1 | COMPOSITIONS AND METHODS FOR CANCER THERAPY | AIM IMMUNOTECH INC. (US) | 2022-03-31 | — | — | US | claimed |
| EP-4746850-A1 | EXTENDED RELEASE DRUG-LOADED MICROPARTICLES | Ferring BV (NL) | 2026-05-27 | — | — | EP | disclosed |
| CN-103665170-A | Peptide therapeutic conjugates and uses thereof | ANGIOCHEM INC | 2014-03-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | BTN3A1, ANTXR2, CLTA | GNRHR 2073/4885PTGS1 4720/4885ABCC2 4265/4885 |
| US-20230165931-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, CD2BP2, CD4 | GNRHR 1335/4885PTGS1 4482/4885ABCC2 4610/4885 |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | GNRHR 3020/4885PTGS1 3834/4885ABCC2 1253/4885 |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | CD2BP2, EPCAM, CD74 | GNRHR 3012/4885PTGS1 4228/4885ABCC2 2527/4885 |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | CD4, DCLRE1A, TOP1 | GNRHR 510/4885PTGS1 3350/4885ABCC2 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.